Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 4Erlotinib Hydrochloride 4Bevacizumab 4temsirolimus 3Radiotherapy 3Carboplatin 3etoposide phosphate 2Sirolimus 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Cetuximab 2Carmustine 2veliparib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sodium thiosulfate 1romidepsin 1picropodophyllin 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1mirdametinib 1irofulven 1efaproxiral 1carotuximab 1cabazitaxel 1acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Spinal Puncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oligodendroglioma × ST 1481 × Clear all
NCT00087061 2013-07-18

Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡